Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.
Ritu Salani, MD
Advertisement
Ritu Salani, MD, MBA, is a board-certified gynecologic oncologist who is a nationally renowned expert in the treatment of gynecologic malignancies with over 15 years of experience. She serves as the Director of Gynecologic Oncology at UCLA.
Articles by Ritu Salani, MD
Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.
Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5